CG
KRYS icon

Cutler Group’s Krystal Biotech KRYS Stock Holding History

Cutler Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-400
Closed -$3K – 4002
2023
Q3 		$3K Hold
400
– – ﹤0.01% 3115
2023
Q2 		$4K Hold
400
– – ﹤0.01% 2728
2023
Q1 		$14K Hold
400
– – ﹤0.01% 2113
2022
Q4 		$16K Hold
400
– – ﹤0.01% 2385
2022
Q3 		$19K Hold
400
– – ﹤0.01% 2657
2022
Q2 		$20K Sell
400
-300
-43% -$18.7K ﹤0.01% 2675
2022
Q1 		$21K Sell
700
-36,300
-98% -$2.27M ﹤0.01% 3021
2021
Q4 		$140K Buy
37,000
+25,400
+219% +$1.48M 0.01% 1596
2021
Q3 		$295K Buy
+11,600
New +$687K 0.01% 1112

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cutler Group's KRYS Position: Q1 2024 in Review

Cutler Group sold out of Krystal Biotech (KRYS) in Q1 2024, closing a stake of 200 shares — an estimated $27.8K sold.

Cutler Group first reported a position in KRYS in Q4 2021 and held it in 9 quarters. The position peaked at $606K in Q4 2021. 234 funds tracked by Wall St. Rank hold KRYS as of Q1 2024.

  • Cutler Group reported no remaining Krystal Biotech position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 200 Krystal Biotech shares in Q1 2024, an estimated $27.8K.
  • Cutler Group first reported a position in Krystal Biotech in Q4 2021 and held it in 9 quarters.
  • Cutler Group's Krystal Biotech position peaked at $606K in Q4 2021.
  • 234 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.